SEC 13F Intelligence

Managers / Q4 2019 · view latest →

Telemetry Investments, L.L.C.

CIK 0001537055 · 152 WEST 36TH STREET, ROOM 402, NEW YORK, NY, 10018-8765 · 212-425-9700

Reported Value
$30M
Q4 2019
Positions
41
Filings on Record
17
2019–present window
Filed
Feb 14, 2020
original filing

Summary

Telemetry Investments, L.L.C. reported $30M in U.S.-listed holdings across 41 positions for Q4 2019.

Its largest position, Wellcare Health Plans, represents 9.6% of the portfolio.

Compared with Q3 2019, the fund opened 13 new positions and exited 25.

Portfolio Metrics

Turnover
+33.6%
vs prior filed quarter
Top-10 Concentration
+57.0%
share of reported value
Largest Position
+9.6%
Wellcare Health Plans
New / Exited
13 / 25
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $157MQ4 ’18Q1 ’19: $197MQ2 ’19: $129MQ2 ’19Q3 ’19: $35MQ4 ’19: $30MQ4 ’19Q1 ’20: $29MQ2 ’20: $37MQ2 ’20Q3 ’20: $46MQ4 ’20: $59MQ4 ’20Q1 ’21: $88MQ2 ’21: $73MQ2 ’21Q3 ’21: $74MQ4 ’21: $78MQ4 ’21Q1 ’22: $63MQ2 ’22: $84MQ2 ’22Q3 ’22: $78Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 69.5%Other: 16.5%ETP: 9.3%US DOMESTIC: 3.3%REIT: 1.4%
  • Common Stock · 69.5% · $21M
  • Other · 16.5% · $5M
  • ETP · 9.3% · $3M
  • US DOMESTIC · 3.3% · $978,000
  • REIT · 1.4% · $432,000

Quarter-over-Quarter Changes full breakdown →

vs Q3 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
EEMISHARES TRNEW+25.0K25.0K+$1M$1M
FEZSPDR INDEX SHS FDSNEW+25.0K25.0K+$1M$1M
RA PHARMACEUTICALS INCNEW+17.1K17.1K+$803,000$803,000
VERASTEM INCNEW+845.0K845.0K+$731,000$731,000
FITBIT INCNEW+101.2K101.2K+$665,000$665,000
KEMET CORPNEW+21.5K21.5K+$582,000$582,000
TALLGRASS ENERGY LPNEW+18.0K18.0K+$398,000$398,000
SYKSTRYKER CORPNEW+1.2K1.2K+$252,000$252,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2019

39 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1WELLCARE HEALTH PLANS INCCOM9.57%$3M8.7K
2ALLERGAN PLCSHS7.45%$2M11.7K
3KDMNKADMON HLDGS INChistory →COM6.95%$2M460.8K
4DERMIRA INCCOM6.85%$2M135.6K
5EIGER BIOPHARMACEUTICALS INCCOM6.74%$2M135.8K
6ZOSANO PHARMA CORPCOM NEW4.36%$1M861.5K
7XTNTXTANT MED HLDGS INChistory →COM NEW4.02%$1M752.9K
8AFFIMED N VCOM3.89%$1M426.1K
9EEMISHARES TRhistory →MSCI EMG MKT ETF3.74%$1M25.0K
10FEZSPDR INDEX SHS FDShistory →EURO STOXX 503.40%$1M25.0K
11ACRSACLARIS THERAPEUTICS INChistory →COM2.78%$833,000441.0K
12RA PHARMACEUTICALS INCCOM2.68%$803,00017.1K
13GLOBALSTAR INCCOM2.51%$754,0001.45M
14VERASTEM INCNOTE 5.000%11/02.44%$731,000845.0K
15FITBIT INCCL A2.22%$665,000101.2K
16GLDSPDR GOLD TRUSThistory →GOLD SHS2.14%$643,0004.5K
17VRAYQVIEWRAY INChistory →COM2.10%$629,000149.0K
18ADMAADMA BIOLOGICS INChistory →COM2.03%$608,000152.0K
19KEMET CORPCOM NEW1.94%$582,00021.5K
20RIGEL PHARMACEUTICALS INCCOM NEW1.61%$483,000225.5K
21MELLANOX TECHNOLOGIES LTDSHS1.48%$444,0003.8K
22ACIAACACIA COMMUNICATIONS INChistory →COM1.36%$407,0006.0K
23SPRINT CORPORATIONCOM1.33%$399,00076.5K
24TALLGRASS ENERGY LPCLASS A SHS1.33%$398,00018.0K
25STEMLINE THERAPEUTICS INCCOM1.25%$375,00035.3K
26EL PASO ELEC COCOM NEW1.04%$311,0004.6K
27NEMNEWMONT GOLDCORP CORPORATIONCOM0.87%$261,0006.0K
28ABXBARRICK GOLD CORPORATIONCOM0.87%$260,00014.0K
29SYKSTRYKER CORPCOM0.84%$252,0001.2K
30NOVAVAX INCNOTE 3.750% 2/00.82%$247,000625.0K
31WRIGHT MED GROUP N VORD SHS0.76%$229,0007.5K
32MPCMARATHON PETE CORPCOM0.76%$228,0003.8K
33CONDOR HOSPITALITY TR INCCOM NEW0.74%$222,00020.1K
34EQREQUITY RESIDENTIALSH BEN INT0.70%$210,0002.6K
35TRACON PHARMACEUTICALS INCCOM NEW0.53%$159,00067.9K
36ENDOLOGIX INCCOM NEW0.43%$129,00081.5K
37BELLEROPHON THERAPEUTICS INCCOM0.39%$118,000338.0K
38ROSEHILL RES INCCL A · *W EXP 04/27/2020.29%$87,000124.4K
39DIPLOMAT PHARMACY INCCOM0.23%$68,00017.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2022Under review146Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$78M177Nov 17, 202213F-HRchanges · EDGAR ↗
Q2 2022$84M177Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$63M165May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$78M178Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$74M160Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$73M139Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$88M126May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$59M89Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$46M73Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$37M65Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$29M54May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$30M41Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$35M53Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$129M82Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$197M101May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$157M136Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.